Decrease of hemostatic cardiovascular risk factors by aggressive vs. Conventional atorvastatin treatment in patients with Type 2 diabetes mellitus

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 8, 2003, Pages 1753-1757

  Van De Ree, M A ^a   De Maat, M P M ^b   Kluft, C ^b   Meinders, A E ^a   Princen, H M G ^b   Huisman, M V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Coagulation; Diabetes mellitus type 2; Fibrinolysis; Statin

Indexed keywords

ATORVASTATIN; BLOOD CLOTTING FACTOR 8A; FIBRINOGEN; HEMOSTATIC AGENT; HEPTANOIC ACID DERIVATIVE; PLACEBO; PYRROLE DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

AGED; ARTICLE; BIOSYNTHESIS; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME;

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR VIIIA; FEMALE; FIBRINOGEN; HEMOSTATICS; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PLACEBOS; PYRROLES; RISK FACTORS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 2142705668     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00357.x     Document Type: Article

References (33)

1. MRC/BHE Heart Protection Study of cholesterol lowering with sim-vastatin in 20,536 high-risk individuals: a randomised placebo-con trolled trial. Lancet 2002; 360: 7-22.
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AMJ. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
3. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N EnglJ Med 1998; 339: 1349-57.
5. Miller GJ. Hemostasis and cardiovascular risk. The British and Eur opean experience. Arch Pathol Lab Med 1992; 116: 1318-21.
6. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.
7. Koh KK. Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol 2000; 76: 23-32.
8. Sirtori CR, Colli S. Influences of lipid-modifying agents on hemostasis. Cardiovasc Drugs Ther 1993; 7: 817-23.
9. Haverkate F, Koopman J, Demaat MPM. Statins and fibrinogen. Lancet 1998; 351: 1430-1.
10. Bickel C, Rupprecht HJ, Blankenberg S, Espinola-Klein C, Rippin G, Hafner G, Lotz J, Prellwitz W, Meyer J. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002; 82: 25-31.
11. Plana JC, Jones PH. The use of statins in acute coronary syndromes: the mechanisms behind the outcomes. Curr Atheroscler Rep 2001; 3: 355-64.
12. Rosenson RS. Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999; 1: 225-32.
13. Dangas G, Smith DA, Unger AH, Shao JH, Meraj P, Fier C, Cohen AM, Fallon JT, Badimon JJ, Ambrose JA. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 2000; 83: 688-92.
14. Knobl P, Schernthaner G, Schnack C, Pietschmann P, Proidl S, Prager R, Vukovich T Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost 1994; 71: 692-7.
15. Ford I, Singh TP, Kitchen S, Makris M, Ward JD, Preston FE. Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. Diabet Med 1991; 8: 322-9.
16. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaac-sohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-33.
17. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001; 24: 1335-41.
18. Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestim-mung des Fibrinogens. Ada Haematol 1957; 17: 237-46.
19. Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf:Ag). Scand J Clin Lab Invest 1987; 47: 143-9.
20. van de Ree MA, Huisman MV, Princen HMG, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129-35.
21. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103: 2323-7.
22. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinsky I, D'Angostino R, Wilson PWF. Hyperinsulinemia, hyperglycemia, and impaired hemostasis-the Framingham off spring study. JAMA 2000; 283: 221-228.
23. Vukovich T, Proidl S, Knobl P, Teufelsbauer H, Schnack C, Scherntha ner G. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients. Thromb Haemost 1992; 68: 253-6.
24. Yoshinari M, Yamamoto M, Wakisaka M, Iwase M, Takano K, Fujishi-ma M. Effect of bezafibrate on hypercoagulability assessed by fluoro-genic prothrombin time in hyperlipidemic patients with non-insulin-dependent diabetes mellitus. Thromb Res 1997; 86: 443-51.
25. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasmino gen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vase Biol 2000; 20: 556-62.
26. Holschermann H, Hilgendorff A, Kemkes-Matthes B, Schonburg M, Bauer EP, Tillmanns H, Haberbosch W Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation 2000; 69: 1830-6.
27. Dangas G, Smith DA, Badimon JJ, Unger AH, Shao JH, Meraj P, Cohen AM, Levine D, Fallon JT, Ambrose JA. Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin. Am J Cardiol 1999; 84: 639-43.
28. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and cor onary artery disease. N Engl J Med 2000; 342: 1792-801.
29. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol 1991; 68: 28B-35B.
30. Flint OP, Masters BA, Gregg RE, Durham SK. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 1997; 145: 99-110.
31. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylger anylation and Rho proteins. Circ Res 1998; 83: 683-90.
32. Essig M, Vrtovsnik F, Nguyen G, Sraer JD, Friedlander G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol 1998; 9: 1377-88.
33. Wierzbicki AS, Lumb PJ, Semra Y, Chik G, Christ ER, Crook MA. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM 1999; 92: 387-94.